Hikma Pharmaceuticals PLC

HIK

Equity

ISIN GB00B0LCW083 / Valor 2324471

LSE London Stock Exchange, SETS (2026-04-30)

GBP 13.98+1.08%

Hikma Pharmaceuticals PLC
UMushroom community rating:

3.14 3 votes No rating yet

NegativeNeutralPositive

About company

Hikma Pharmaceuticals PLC is a London‑listed pharmaceutical company, founded in Jordan and headquartered in London, that develops, manufactures and commercialises a broad range of branded and generic medicines across the United States, the Middle East & North Africa and Europe. Its core operations cover three main areas—injectable medicines (including sterile hospital injectables), generic oral medicines and branded generics for regional markets—supplied through its own manufacturing sites and commercial networks to hospitals, wholesalers and retail pharmacies. The company combines in‑house development and manufacturing with licensing and partnerships to bring off‑patent and complex generic products to market, with a particular emphasis on injectable and hospital-use therapies.

Summarized from source with an LLMView SourceSector: Healthcare

Performance overview

Hikma Pharmaceuticals PLC (Q4 2025 / full‑year 2025): The report describes group revenue and profit growth for 2025 but does not publish specific revenue, profit, margin or EPS numbers in the excerpt supplied.

Capital returns

The company announced a share buyback alongside its results (press release dated 26 February 2026). The excerpt contains no information on the size, timing or authorization of the buyback.

Leadership changes

Hikma notes leadership changes in its results communications; the excerpt references Khalid Nabilsi as Deputy CEO, North America and Europe. No further appointment or departure details are included in the provided text.

Product launches

Hikma launched authorised generics of Nucynta (tapentadol) and Nucynta ER in the US (press releases on 25 Feb and 11 Mar 2026), indicating continued commercial activity in the US generics/specialty market.

Strategy and investments

The company states it continued to invest in people, capabilities and infrastructure throughout 2025 to support access to medicines and long‑term value creation; the excerpt presents this as a strategic focus without financial quantification.

Data limitations

The provided company excerpt lacks numeric financial details (actual revenue, profit amounts, margins, EPS, segment breakdowns or cash flow). For precise figures and quarter-level metrics, consult Hikma’s full results press release or the published annual report. Summarized from source with an LLMView Source

Key figures

-29.5%1Y

-24.0%3Y

-41.9%5Y

Performance

34.6%1Y

27.4%3Y

28.2%5Y

Volatility